Biotech Values

[rkrw]

The others haven't been approved. That would be precedent setting, settling with competitors that haven't even been approved and likely won't. The upshot to Sanofi is settle and face 3 competitors, pricing gets squashed, or don't settle and if mnta does get approved, have 1 competitor and split the dollar value of the market. It's an interesting model. I'd also look for mnta to settle with the two challengers, throw them a carrot for their troubles. mnta has Sandoz behind them which should help.